Medical technology company developing devices for cardiology, endoscopy, urology, neuromodulation, and other specialty procedures.
Profile & Fundamentals
Boston Scientific: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Boston Scientific Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Company profile record
Boston Scientific Corp
Common Stock · Health Care · Health Care Equipment
Company
- Company / asset
- Boston Scientific Corp
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Health Care Equipment
- HQ
- 🇺🇸 United States
- Head office
- 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234
Leadership & scale
- Chief executive
- Mr. Michael F. Mahoney
- CEO year born
- 1965
- Full-time employees
- 59K
- Fiscal year end
- December
- IPO date
- 1992-05-18
Fundamentals snapshot
- Market Cap
- USD 64.4B
- P/E
- 17.5x
- Revenue (Q2 26)
- USD 5.4B
- Profit (Q2 26)
- USD 907.0M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 20.1B
- Shares in public float
- 1.4B
- Insider ownership
- 0.25%
Reporting & identifiers
- Symbol
- BSX.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US1011371077
- Asset ID
- equity_55b13a19-f596-5d01-addd-94c29b3953c9
Ownership
Shares Outstanding
- Shares outstanding
Top holders
- BlackRock Inc131,822,037 shares · 9.10% · Reported 2026-03-31
- Vanguard Capital Management, LLC96,411,568 shares · 6.65% · Reported 2026-03-31
- FMR Inc74,226,395 shares · 5.12% · Reported 2026-03-31
- State Street Corp67,986,847 shares · 4.69% · Reported 2026-03-31
- PRIMECAP Management Company50,520,914 shares · 3.49% · Reported 2026-06-30
- Vanguard MStar Total Stk Mkt Idx Invest47,324,803 shares · 3.27% · Reported 2026-07-31
- Vanguard 500 Index Investor39,020,916 shares · 2.69% · Reported 2026-07-31
View more holders (8)
- JPMorgan Chase & Co33,350,157 shares · 2.30% · Reported 2026-03-31
- Geode Capital Management, LLC33,285,757 shares · 2.30% · Reported 2026-03-31
- Vanguard PRIMECAP Inv30,883,039 shares · 2.13% · Reported 2026-06-30
- Vanguard Portfolio Management, LLC29,796,211 shares · 2.06% · Reported 2026-03-31
- D. E. Shaw & Co LP25,457,409 shares · 1.76% · Reported 2026-06-30
- Bank of America Corp22,756,646 shares · 1.57% · Reported 2026-03-31
- Morgan Stanley - Brokerage Accounts22,266,664 shares · 1.54% · Reported 2026-03-31
- NORGES BANK21,170,029 shares · 1.46% · Reported 2026-06-30
Earnings, Profitability & Valuation
Earnings & Revenue
Revenue, Net Income, and Free Cash Flow
- Revenue
- Free cash flow
- Net income
Valuation
Historical P/E Ratio
- Published P/E
Profitability & Margins
Profitability Margins
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.